Table 1.
Characteristic | n (%) (N = 45) |
---|---|
Median age, y (range) | 66 (50–86) |
Sex | |
Male | 20 (44) |
Female | 25 (56) |
Race | |
White | 37 (82) |
Black | 6 (13) |
Other | 2 (5) |
Current or former smoker | 44 (98) |
Brain metastases | 10 (22) |
Chemotherapy cycles | |
4 | 23 (51) |
5–6 | 22 (49) |
Median time to first dose of pembrolizumab, wk (range) | 5 (3–9) |
Measurable disease | 34 (76) |